Related Experiment Video

Updated: Jan 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

JCL Roundtable: Novel therapies in lipid management

Steven E Nissen1, Ann Marie Navar2, Daniel Gaudet3

  • 1Cleveland Clinic, Cleveland, OH (Dr Nissen).

Journal of Clinical Lipidology
|October 11, 2025
PubMed

Insights

Novel lipid management options, including bempedoic acid and obicetrapib, offer new ways to prevent atherosclerotic cardiovascular disease (ASCVD). These agents target key lipid markers, improving primary prevention strategies for cardiovascular health.

Area of Science:

  • Cardiology
  • Pharmacology
  • Lipidology

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) remains a primary cause of death and disability.
  • Effective management of lipid profiles is crucial for ASCVD prevention and treatment.
  • Current therapeutic options have limitations, necessitating the development of novel agents.

Purpose of the Study:

  • To discuss emerging lipid management strategies for ASCVD.
  • To review recently approved and investigational lipid-lowering agents.
  • To highlight the role of novel therapies in primary ASCVD prevention.

Main Methods:

  • A roundtable discussion format involving key opinion leaders in lipidology.
  • Review of novel lipid management options, including bempedoic acid and obicetrapib.
  • Discussion of targeted lipid parameters such as LDL-C, Lp(a), Apo B, and triglycerides.

Main Results:

  • Bempedoic acid (ATP-citrate lyase inhibitor) and obicetrapib (CETP inhibitor) are discussed as novel therapeutic options.
  • Apolipoprotein C3 (Apo C3) inhibiting agents are also highlighted for their potential.
  • These agents target multiple atherogenic lipid particles and proteins, including LDL-C, Lp(a), Apo B, triglycerides, remnant cholesterol, and chylomicrons.
  • Emphasis on the importance of primary prevention by addressing risk factors before major adverse cardiovascular events occur.

Conclusions:

  • Novel lipid-lowering agents represent a significant advancement in managing dyslipidemias.
  • These agents offer promising new tools for clinicians in the primary prevention of ASCVD.
  • The discussants expressed optimism regarding the integration of these therapies into clinical practice.

Keywords:
Apolipoprotein C3Bempedoic acidCholesteryl ester transfer protein inhibitorLipoprotein(a)Low-density lipoprotein cholesterolObicetrapib

More Related Videos

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.5K
Lipidomics and Transcriptomics in Neurological Diseases09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.9K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
460
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.8K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
867
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
621